This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Indications for testing for proteinuria

Authoring team

Indications for testing for proteinuria

Dipstick urinalysis for protein is indicated

  • As part of the initial assessment of patients with
    • if a patient has a newly discovered GFR < 60 ml/min/1.73 m2
    • if a patient has newly discovered haematuria
    • newly diagnosed hypertension
    • if there is unexplained oedema
    • in cases of suspected heart failure
    • suspected multisystem disease, e.g. SLE, systemic vasculitis
    • diabetes mellitus
  • As part of the annual monitoring of patients with
    • biopsy-proven glomerulonephritis
    • reflux nephropathy
    • asymptomatic microscopic haematuria
    • asymptomatic proteinuria
    • Diabetes mellitus (patients with diabetes mellitus should also have annual testing for albumin:creatinine ratio if the dipstick urinalysis for protein is negative)
  • Monitoring for proteinuria is also required for patients receiving treatment with gold and penicillamine
    • recommendations for frequency of monitoring in the British National Formulary:
      • penicillamine
        • before commencing treatment and then every 1-2 weeks for the first 2 months, monthly thereafter, and in the week after any dose increase
      • intramuscular gold
        • before each intramuscular injection
        • for oral gold, monthly

Reference:

  1. The Renal Association (May 2006).UK CKD Guidelines

 


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.